Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment

Results from the latest phase 3 clinical trial testing combinations of immunotherapy and tyrosine-kinase inhibitors for advanced kidney cancer improve standard first-line treatment options for patients.

Automated summary

Results from the latest phase 3 clinical trial show that combinations of immunotherapy and tyrosine-kinase inhibitors improve standard first-line treatment options for patients with advanced kidney cancer.